Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome

risomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ systems, including the face and underlying skeleton. Besides causing stigmata, these facial dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To investigate the therap...

ver descrição completa

Detalhes bibliográficos
Autores: Starbuck, John M., Llambrich, Sergi, González, Rubén, Albaigès, Júlia, Sarlé, Anna, Wouters, Jens, González, Alejandro, Sevillano, Xavier, Sharpe, James, De la Torre, Rafael, Dierssen, Mara, Vande Velde, Greetje, Martínez Abadías, Neus, 1978-
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/175252
Acesso em linha:https://hdl.handle.net/2445/175252
Access Level:acceso abierto
Palavra-chave:Cromosomes
Síndrome de Down
Te
Chromosomes
Down syndrome
Tea
id ES_c372fa5df975f8ab81eae0ff5e342994
oai_identifier_str oai:diposit.ub.edu:2445/175252
network_acronym_str ES
network_name_str España
repository_id_str
spelling Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndromeStarbuck, John M.Llambrich, SergiGonzález, RubénAlbaigès, JúliaSarlé, AnnaWouters, JensGonzález, AlejandroSevillano, XavierSharpe, JamesDe la Torre, RafaelDierssen, MaraVande Velde, GreetjeMartínez Abadías, Neus, 1978-CromosomesSíndrome de DownTeChromosomesDown syndromeTearisomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ systems, including the face and underlying skeleton. Besides causing stigmata, these facial dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To investigate the therapeutic potential of green tea extracts containing epigallocatechin-3-gallate (GTE-EGCG) for alleviating facial dysmorphologies associated with DS, we performed an experimental study with continued pre- and postnatal treatment with two doses of GTE-EGCG supplementation in a mouse model of DS, and an observational study of children with DS whose parents administered EGCG as a green tea supplement. We evaluated the effect of high (100 mg/kg/day) or low doses (30 mg/kg/day) of GTE-EGCG, administered from embryonic day 9 to post-natal day 29, on the facial skeletal development in the Ts65Dn mouse model. In a cross-sectional observational study, we assessed the facial shape in DS and evaluated the effects of self-medication with green tea extracts in children from 0 to 18 years old. The main outcomes are 3D quantitative morphometric measures of the face, acquired either with micro-computed tomography (animal study) or photogrammetry (human study). The lowest experimentally tested GTE-EGCG dose improved the facial skeleton morphology in a mouse model of DS. In humans, GTE-EGCG supplementation was associated with reduced facial dysmorphology in children with DS when treatment was administered during the first 3 years of life. However, higher GTE-EGCG dosing disrupted normal development and increased facial dysmorphology in both trisomic and euploid mice. We conclude that GTE-EGCG modulates facial development with dose-dependent effects. Considering the potentially detrimental effects observed in mice, the therapeutic relevance of controlled GTE-EGCG administration towards reducing facial dysmorphology in young children with Down syndrome has yet to be confirmed by clinical studies.Nature Publishing Group2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/175252Articles publicats en revistes (Biologia Evolutiva, Ecologia i Ciències Ambientals)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1038/s41598-021-83757-1Scientific Reports, 2021, vol. 11, num. 4715https://doi.org/10.1038/s41598-021-83757-1cc-by (c) Starbuck, John M. et al., 2021http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1752522026-05-27T06:46:51Z
dc.title.none.fl_str_mv Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
title Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
spellingShingle Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
Starbuck, John M.
Cromosomes
Síndrome de Down
Te
Chromosomes
Down syndrome
Tea
title_short Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
title_full Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
title_fullStr Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
title_full_unstemmed Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
title_sort Green tea extracts containing Epigallocatechin-3-Gallate modulate facial development in Down syndrome
dc.creator.none.fl_str_mv Starbuck, John M.
Llambrich, Sergi
González, Rubén
Albaigès, Júlia
Sarlé, Anna
Wouters, Jens
González, Alejandro
Sevillano, Xavier
Sharpe, James
De la Torre, Rafael
Dierssen, Mara
Vande Velde, Greetje
Martínez Abadías, Neus, 1978-
author Starbuck, John M.
author_facet Starbuck, John M.
Llambrich, Sergi
González, Rubén
Albaigès, Júlia
Sarlé, Anna
Wouters, Jens
González, Alejandro
Sevillano, Xavier
Sharpe, James
De la Torre, Rafael
Dierssen, Mara
Vande Velde, Greetje
Martínez Abadías, Neus, 1978-
author_role author
author2 Llambrich, Sergi
González, Rubén
Albaigès, Júlia
Sarlé, Anna
Wouters, Jens
González, Alejandro
Sevillano, Xavier
Sharpe, James
De la Torre, Rafael
Dierssen, Mara
Vande Velde, Greetje
Martínez Abadías, Neus, 1978-
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cromosomes
Síndrome de Down
Te
Chromosomes
Down syndrome
Tea
topic Cromosomes
Síndrome de Down
Te
Chromosomes
Down syndrome
Tea
description risomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ systems, including the face and underlying skeleton. Besides causing stigmata, these facial dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To investigate the therapeutic potential of green tea extracts containing epigallocatechin-3-gallate (GTE-EGCG) for alleviating facial dysmorphologies associated with DS, we performed an experimental study with continued pre- and postnatal treatment with two doses of GTE-EGCG supplementation in a mouse model of DS, and an observational study of children with DS whose parents administered EGCG as a green tea supplement. We evaluated the effect of high (100 mg/kg/day) or low doses (30 mg/kg/day) of GTE-EGCG, administered from embryonic day 9 to post-natal day 29, on the facial skeletal development in the Ts65Dn mouse model. In a cross-sectional observational study, we assessed the facial shape in DS and evaluated the effects of self-medication with green tea extracts in children from 0 to 18 years old. The main outcomes are 3D quantitative morphometric measures of the face, acquired either with micro-computed tomography (animal study) or photogrammetry (human study). The lowest experimentally tested GTE-EGCG dose improved the facial skeleton morphology in a mouse model of DS. In humans, GTE-EGCG supplementation was associated with reduced facial dysmorphology in children with DS when treatment was administered during the first 3 years of life. However, higher GTE-EGCG dosing disrupted normal development and increased facial dysmorphology in both trisomic and euploid mice. We conclude that GTE-EGCG modulates facial development with dose-dependent effects. Considering the potentially detrimental effects observed in mice, the therapeutic relevance of controlled GTE-EGCG administration towards reducing facial dysmorphology in young children with Down syndrome has yet to be confirmed by clinical studies.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/175252
url https://hdl.handle.net/2445/175252
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41598-021-83757-1
Scientific Reports, 2021, vol. 11, num. 4715
https://doi.org/10.1038/s41598-021-83757-1
dc.rights.none.fl_str_mv cc-by (c) Starbuck, John M. et al., 2021
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Starbuck, John M. et al., 2021
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv Articles publicats en revistes (Biologia Evolutiva, Ecologia i Ciències Ambientals)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418796631982080
score 15,198674

Registos relacionados